Page 320 - Read Online

Gooding et al. J Cancer Metastasis Treat 2019;5:41 I http://dx.doi.org/10.20517/2394-4722.2019.11 Page 11 of 14

DECLARATIONS
Acknowledgments
Members of the Schiemann Laboratory are thanked for critical comments and reading of the manuscript.

Authors' contributions
Conception and study design: Gooding AJ, Parker KA, Schiemann WP
Drafted and revised the manuscript: Gooding AJ, Parker KA, Valadkhan S, Schiemann WP

Availability of data and materials
Not applicable.

Financial support and sponsorship
Research support was provided in part by the National Institutes of Health (CA236273) to Schiemann
WP and Valadkhan S, and (T32GM007250 and F30CA203233) to Gooding AJ. Additional support was
graciously provided by the METAvivor Foundation to Schiemann WP, and by pilot funding from the Case
Comprehensive Cancer Center’s Research Innovation Fund, which is supported by the Case Council and
Friends of the Case Comprehensive Cancer Center to Schiemann WP.

Conflicts of interest
All authors declare that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2019;69:7-34.
2. Welch HG, Prorok PC, O'Malley AJ, Kramer BS. Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N
Engl J Med 2016;375:1438-47.
3. Arendt LM, Kuperwasser C. Form and function: how estrogen and progesterone regulate the mammary epithelial hierarchy. J Mammary
Gland Biol Neoplasia 2015;20:9-25.
4. Gingras I, Gebhart G, de Azambuja E, Piccart-Gebhart M. HER2-positive breast cancer is lost in translation: time for patient-centered
research. Nat Rev Clin Oncol 2017;14:669-81.
5. Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer--the present. Histopathology 2008;52:82-90.
6. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple- negative breast cancer. Clin Breast Cancer
2009;9:S73-81.
7. Costa RLB, Gradishar WJ. Triple-negative breast cancer: current practice and future directions. J Oncol Pract 2017;13:301-3.
8. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:341-52.
9. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
10. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. Triple-negative breast cancer: clinical features and patterns of recurrence.
Clin Cancer Res 2007;13:4429-34.
11. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448- 56.
12. Vanharanta S, Massague J. Origins of metastatic traits. Cancer Cell 2013;24:410-21.
13. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, et al. Isolation and characterization of circulating tumor cells from patients with
localized and metastatic prostate cancer. Sci Transl Med 2010;2:25ra23.
14. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, et al. Isolation of rare circulating tumour cells in cancer patients by microchip
technology. Nature 2007;450:1235-9.
15. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, et al. Multistep nature of metastatic inefficiency: dormancy of solitary